UniQure reports promising data from gene therapy trial

Your Health Matters

(Reuters) – Dutch biotech UniQure NV said its experimental gene therapy for a blood clotting disorder benefited some patients in an early-stage study. The drug is being developed to treat hemophilia B, a condition caused by the deficiency of a the factor IX gene. (Reporting by Amrutha Penumudi in Bengaluru)
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave